Cargando…

Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus

OBJECTIVE: Interleukin-26 (IL-26) has a unique ability to activate innate immune cells due to its binding to circulating double-stranded DNA. High levels of IL-26 have been reported in patients with chronic inflammation. We aimed to investigate IL-26 levels in patients with systemic lupus erythemato...

Descripción completa

Detalles Bibliográficos
Autores principales: Brilland, Benoit, Bach-Bunner, Maxime, Gomes, Christopher Nunes, Larochette, Vincent, Foucher, Etienne, Plaisance, Marc, Saulnier, Patrick, Costedoat-Chalumeau, Nathalie, Ghillani, Pascale, Belizna, Cristina, Delneste, Yves, Augusto, Jean-François, Jeannin, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160525/
https://www.ncbi.nlm.nih.gov/pubmed/34054830
http://dx.doi.org/10.3389/fimmu.2021.663192
_version_ 1783700304684908544
author Brilland, Benoit
Bach-Bunner, Maxime
Gomes, Christopher Nunes
Larochette, Vincent
Foucher, Etienne
Plaisance, Marc
Saulnier, Patrick
Costedoat-Chalumeau, Nathalie
Ghillani, Pascale
Belizna, Cristina
Delneste, Yves
Augusto, Jean-François
Jeannin, Pascale
author_facet Brilland, Benoit
Bach-Bunner, Maxime
Gomes, Christopher Nunes
Larochette, Vincent
Foucher, Etienne
Plaisance, Marc
Saulnier, Patrick
Costedoat-Chalumeau, Nathalie
Ghillani, Pascale
Belizna, Cristina
Delneste, Yves
Augusto, Jean-François
Jeannin, Pascale
author_sort Brilland, Benoit
collection PubMed
description OBJECTIVE: Interleukin-26 (IL-26) has a unique ability to activate innate immune cells due to its binding to circulating double-stranded DNA. High levels of IL-26 have been reported in patients with chronic inflammation. We aimed to investigate IL-26 levels in patients with systemic lupus erythematosus (SLE). METHODS: IL-26 serum levels were quantified by ELISA for 47 healthy controls and 109 SLE patients previously enrolled in the PLUS study. Performance of IL-26 levels and classical markers (autoantibodies or complement consumption) to identify an active SLE disease (SLE disease activity index (SLEDAI) score > 4) were compared. RESULTS: IL-26 levels were significantly higher in SLE patients than in controls (4.04 ± 11.66 and 0.74 ± 2.02 ng/mL; p = 0.005). IL-26 levels were also significantly higher in patients with active disease than those with inactive disease (33.08 ± 21.06 vs 1.10 ± 3.80 ng/mL, p < 0.0001). IL-26 levels correlated with SLEDAI score and the urine protein to creatinine ratio (uPCR) (p < 0.001). Patients with high IL-26 levels had higher SLEDAI score, anti-DNA antibodies levels, and uPCR (p < 0.05). They presented more frequently with C3 or C4 complement consumption. Lastly, IL-26 showed stronger performance than classical markers (complement consumption or autoantibodies) for active disease identification. CONCLUSIONS: Our results suggest that, in addition to classical SLE serological markers, the measurement of IL-26 levels may be a useful biomarker for active disease identification in SLE patients.
format Online
Article
Text
id pubmed-8160525
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81605252021-05-29 Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus Brilland, Benoit Bach-Bunner, Maxime Gomes, Christopher Nunes Larochette, Vincent Foucher, Etienne Plaisance, Marc Saulnier, Patrick Costedoat-Chalumeau, Nathalie Ghillani, Pascale Belizna, Cristina Delneste, Yves Augusto, Jean-François Jeannin, Pascale Front Immunol Immunology OBJECTIVE: Interleukin-26 (IL-26) has a unique ability to activate innate immune cells due to its binding to circulating double-stranded DNA. High levels of IL-26 have been reported in patients with chronic inflammation. We aimed to investigate IL-26 levels in patients with systemic lupus erythematosus (SLE). METHODS: IL-26 serum levels were quantified by ELISA for 47 healthy controls and 109 SLE patients previously enrolled in the PLUS study. Performance of IL-26 levels and classical markers (autoantibodies or complement consumption) to identify an active SLE disease (SLE disease activity index (SLEDAI) score > 4) were compared. RESULTS: IL-26 levels were significantly higher in SLE patients than in controls (4.04 ± 11.66 and 0.74 ± 2.02 ng/mL; p = 0.005). IL-26 levels were also significantly higher in patients with active disease than those with inactive disease (33.08 ± 21.06 vs 1.10 ± 3.80 ng/mL, p < 0.0001). IL-26 levels correlated with SLEDAI score and the urine protein to creatinine ratio (uPCR) (p < 0.001). Patients with high IL-26 levels had higher SLEDAI score, anti-DNA antibodies levels, and uPCR (p < 0.05). They presented more frequently with C3 or C4 complement consumption. Lastly, IL-26 showed stronger performance than classical markers (complement consumption or autoantibodies) for active disease identification. CONCLUSIONS: Our results suggest that, in addition to classical SLE serological markers, the measurement of IL-26 levels may be a useful biomarker for active disease identification in SLE patients. Frontiers Media S.A. 2021-05-14 /pmc/articles/PMC8160525/ /pubmed/34054830 http://dx.doi.org/10.3389/fimmu.2021.663192 Text en Copyright © 2021 Brilland, Bach-Bunner, Gomes, Larochette, Foucher, Plaisance, Saulnier, Costedoat-Chalumeau, Ghillani, Belizna, Delneste, Augusto and Jeannin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Brilland, Benoit
Bach-Bunner, Maxime
Gomes, Christopher Nunes
Larochette, Vincent
Foucher, Etienne
Plaisance, Marc
Saulnier, Patrick
Costedoat-Chalumeau, Nathalie
Ghillani, Pascale
Belizna, Cristina
Delneste, Yves
Augusto, Jean-François
Jeannin, Pascale
Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus
title Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus
title_full Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus
title_fullStr Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus
title_full_unstemmed Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus
title_short Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus
title_sort serum interleukin-26 is a new biomarker for disease activity assessment in systemic lupus erythematosus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160525/
https://www.ncbi.nlm.nih.gov/pubmed/34054830
http://dx.doi.org/10.3389/fimmu.2021.663192
work_keys_str_mv AT brillandbenoit seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT bachbunnermaxime seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT gomeschristophernunes seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT larochettevincent seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT foucheretienne seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT plaisancemarc seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT saulnierpatrick seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT costedoatchalumeaunathalie seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT ghillanipascale seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT beliznacristina seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT delnesteyves seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT augustojeanfrancois seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus
AT jeanninpascale seruminterleukin26isanewbiomarkerfordiseaseactivityassessmentinsystemiclupuserythematosus